PULMATRIX, INC. Additional Paid in Capital, Common Stock
PULMATRIX, INC. (PULM) had Additional Paid in Capital, Common Stock of $226.18 million as of 2019-12-31, per its 10-K filed 2020-03-26.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2020-03-26
- 2019-12-31: Additional Paid in Capital, Common Stock $226.18M.
- 2019-09-30: Additional Paid in Capital, Common Stock $225.84M.
- 2019-06-30: Additional Paid in Capital, Common Stock $225.66M.
- 2019-03-31: Additional Paid in Capital, Common Stock $209.92M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2019-12-31 | $226.18M 10-K · filed 2020-03-26 | |
| 2019-09-30 | $225.84M 10-Q · filed 2019-11-01 | |
| 2019-06-30 | $225.66M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | $209.92M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $206.41M 10-K · filed 2020-03-26 | |
| 2018-09-30 | $202.86M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $202.20M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $186.75M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $184.14M 10-K · filed 2019-02-19 | $184.14M 10-K · filed 2018-03-13 |
| 2017-09-30 | $182.26M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $180.81M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $175.33M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $164.71M 10-K · filed 2018-03-13 | |
| 2016-09-30 | $163.59M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $163.11M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $161.94M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $160.71M 10-K · filed 2017-03-10 | |
| 2015-09-30 | $159.47M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $157.94M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $20.40M 10-K · filed 2015-06-10 | |
| 2014-12-31 | $23.14M 10-K · filed 2016-03-10 | $20.10M 10-Q · filed 2015-02-13 |
| 2014-03-31 | $18.30M 10-K · filed 2015-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |